Mallinckrodt Takes Out Sucampo in Surprising $1.2B Deal Post author:Sam Post published:December 26, 2017 Post category:BioPharma Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds. Source: BioSpace You Might Also Like How This Drug Candidate Could be a Winner in Gilead's Pipeline March 20, 2017 Despite Recent Layoffs, Eli Lilly to Invest $850 Million in U.S. Operations March 23, 2017 4 Critical Takeaways From 3D Systems??? Q4 Earnings Call March 6, 2017
